Different COVID-19 treatments’ impact on hospital length of stay

被引：0
作者：
Satori Iwamoto
Bahaar Kaur Muhar
Hao Chen
Harrison Chu
Mason Johnstone
Ashwin Sidhu
Hillary Chu
Joseph Fischer
Gary Chu
机构：
[1] California Northstate University College of Medicine,Department of Respiratory Internal Medicine
[2] Yokohama City University,undefined
来源：
European Journal of Medical Research | / 28卷
关键词：
COVID-19; Length of stay; Mortality;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Question: Is the three-drug combination therapy of dexamethasone, remdesivir, and tocilizumab effective in decreasing the length of stay for patients with severe COVID-19 disease?.Findings: The three-drug combination of remdesivir, dexamethasone, and tocilizumab decreased LOS by 8 days (p=0.0034) compared to nonviable treatments like hydroxychloroquine and convalescent plasma transfusion. However, it did not show any statistically significant benefit when compared to two-drug regimens (dexamethasone plus remdesivir) in severe COVID-19 (p=0.116). No treatment arm appeared to show a statistically significant decrease in mortality for severe COVID-19 patients.Meaning: Triple drug therapies that include tocilizumab may potentially reduce LOS for severe patients but we did not find statistically significant data to support this statement
引用
收藏
相关论文
共 577 条
[1]  
Muhar BK(2022)The race for COVID-19 vaccines: the various types and their strengths and weaknesses J Pharm Pract 36 30-38
[2]  
Nehira J(2021)Insights into neurological dysfunction of critically ill COVID-19 patients Trends Anaesthesia Critical Care 51 3372-3390
[3]  
Malhotra A(2022)Acute ischemic stroke in a young woman with an otherwise asymptomatic SARS-CoV-2 infection J Med Res Surg 8 402-409
[4]  
Kotchoni SO(2021)An update of anti-viral treatment of COVID-19 Turk J Med Sci 384 693-704
[5]  
Deana C(2022)Predicting oxygen utilization & nurse staffing needs for SARS-CoV-2 J Bioinform Neurosci 10 888-899
[6]  
Verriello L(2021)Dexamethasone in hospitalized patients with Covid-19 N Engl J Med 324 1307-1316
[7]  
Pauletto G(2022)Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial Lancet Respir Med 59 1637-1645
[8]  
Corradi F(2020)Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial JAMA 397 38-47
[9]  
Forfori F(2020)The journey of remdesivir: from Ebola to COVID-19 Drugs Context 17 639970-63
[10]  
Cammarota G(2021)An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment Drug Resist Updat 82 2224-184
12345678910